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Abstract
Background: Infection is a major complication of cerebrospinal fluid shunting procedures. The present report
assesses the efficacy of such catheters in both shunts and external ventricular drains (EVDs) against infection and
particularly against Staphylococcus spp. infection.
Methods: All shunt and EVD procedures performed by means of antibiotic-impregnated catheters (AICs) and non-
AICs during the period of study were registered. In cases of shunt procedures, a minimal follow-up of 90 days was
considered, as well as de novo insertion and catheter revisions. Single valve revisions were not included. In cases
of EVD procedures, those catheters removed before the fifth post-insertion day were not included. A total of 119
cerebrospinal fluid shunting procedures performed with AICs were studied in comparison with 112 procedures
performed by means of non-AICs.
Results: Antibiotic-impregnated catheters were associated with a significant decrease in both overall and
staphylococcal infection (p = 0.030 and p = 0.045, respectively). The number needed to treat for AICs was 8 to
prevent one infection and 14 to prevent one staphylococcal infection. When comparing with shunts, the use of
EVDs was associated with a 37-fold increased likelihood of infection.
Conclusions: Antibiotic-impregnated catheters are a safe and helpful tool to reduce CSF shunting device-related
infections.
Background
Infection is a major complication of cerebrospinal fluid
(CSF) shunting devices. It involves higher morbidity and
mortality for patients but higher costs for the hospital as
well [1-10]. In the last decades preventive measures have
focused on surgical technique, the use of peri-operative
antibiotic prophylaxis and implanted devices. Catheters
coverage with antibiotics or antiseptics has been one of
the latest measures to be considered [11-35]. The aim of
such measure is the slow delivery of the drug along the
early postoperative period (which is theoretically the
moment of higher risk) in order to avoid bacterial
adherence to the catheter [18,36,37]. One of the first
studies in this regard was published by Gower et al. [38]
in 1985. The author employed catheters soaked up in
Bacitracin A for 30 minutes, which resulted in a reduc-
tion of 54% of Staphylococcus epidermidis adherence to
the catheter surface.
The development of CSF shunting devices impreg-
nated with antiseptic or antibiotic agents has focused on
preventing Staphylococcus spp. infections and particu-
larly those ones caused by biofilm-producer Staphylo-
cocci strains, since these latter have been shown to be
the main causative pathogens [39]. Although many
authors defend the protective effect of AICs against
infection in shunt procedures, there is short experience
with external ventricular drains (EVDs). Besides that,
only overall infection effect has been considered in most
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tective effect of AICs [11-15,18,19,25-27,29].
Clinical observation at our centre has led to believe
that AICs are not only associated with a lower risk of
staphylococcal infection, but to a higher risk of gram-
negative bacilli (GNB) infection. This suspicion was par-
tially confirmed in a preliminary study carried out at
o u rc e n t r e[ 1 7 ] .T h ea i mo ft h ep r e s e n ts t u d yi st o
assess the efficacy of rifampicin and clindamycin
impregnated CSF shunting devices against infection and
particularly staphylococcal infection, as well as the effect
of such catheters against GNB infection.
Methods
A single-centre, retrospective cohort study was designed
to assess the efficacy of EVDs and shunts impregnated
with rifampicin and clindamycin against infection (Bac-
tiseal; Codman, Johnson & Johnson, Raynham, MA,
USA) when comparing them with non-impregnated
devices.
Patients selection
All patients who underwent CSF shunt placement at
our centre during the period of study from January 1
st
2004 to October 31
st 2008 were reported. The proce-
dures included both de novo insertion and shunt revi-
sions (ventricular catheter, distal catheter or full
revision). Single valve substitution was not included, as
this part of the shunt is never impregnated and so, indi-
vidual substitution should not influence in the event to
be studied. A minimal follow-up of 90 days was consid-
ered. All patients who underwent an EVD insertion at
our centre and kept the catheter for at least 5 days dur-
ing the period of study from January 1
st 2006 to Octo-
ber 31
st 2008 were also included. Emergency and
elective procedures were considered. Both dates of
initial data collection correspond to the introduction of
AICs in the regular clinical practice at our centre. Prior
a p p r o v a lf o rA I C su s ew a so b t a i n e df r o mt h ei n s t i t u -
tional review board. Procedures were assigned to the
treatment cohort when rifampicin (0.054%) and clinda-
mycin (0.15%) impregnated catheters ("Bactiseal"; Cod-
man, Johnson & Johnson, Raynham, MA, USA) were
employed and to the control cohort when non-AICs
were implanted.
The presence of known allergy to rifampicin or clinda-
mycin was the only strict exclusion criterion for the
insertion of AICs. Clinical indication for shunt proce-
dures was CSF shunting in every case. In EVDs, need of
intracranial pressure monitoring was also included. The
choice of AICs versus non-AICs was a decision solely
made by the neurosurgeon in charge in all cases.
No changes were made in surgical technique or peri-
operative patient care. Written informed consent was
obtained from patients or representatives in every
elective procedure and when possible in emergency
procedures.
A total of 231 procedures (119 shunts and 112 EVDs)
performed in 171 patients were included for final analy-
sis. Antibiotic-impregnated catheters were employed in
119 of them, using non-AICs in the 112 remaining
procedures.
Dependent variable: infection
Infection was defined by positive result of CSF or/and
surgical wound exudation culture, independently from
catheter culture result. Positive result required the same
microorganism grew on two consecutive positive sam-
ples when contamination was suspected.
Independent variables
Epidemiological, clinical and surgical variables were
registered from every procedure included in the data-
base (Table 1).
Statistical analysis
Database information was processed and analyzed by
means of SPSS 15.0 for Windows.
Descriptive statistics
Numerical variables represented by the mean were con-
trasted with U Mann-Whitney test whereas those repre-
sented by the median were contrasted with Median test.
Chi-square test or Exact Fisher test were used for cate-
gorical variables.
Analytic statistics
The proportion of infected devices as a function of the
length of time they had been in place were compared
between both cohorts by means of univariate Cox
regression analysis and log-rank test on Kaplan-Meier
estimates. Infection-free survival was analyzed by means
of multivariate Cox regression model in order to esti-
mate the simultaneous effects of independent variables
on the incidence of device-related infection. Propor-
tional hazard ratios (HRs) with 95% confidence intervals
(CIs) were calculated.
A stratified analysis depending on the type of device
placed (EVD versus shunt) was performed in order to
adjust for possible confounding variables. In the multi-
variate analysis concerning shunts, and with the aim of
preserving the test statistical power due to the low inci-
dence of infectious events, the most relevant confound-
ing variable was identified. Then, the independent
variable to be studied (AICs) and those variables that
were significant at a p v a l u eo f0 . 0 5o rl e s si nt h eu n i -
variate Cox analysis were entered in a stepwise fashion
into multivariate Cox regression models and tested for
an independent effect.
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sidered level of significance was 5%. All p values were
based on two-tailed tests of significance.
Results
A total of 231 procedures performed in 171 patients
were included for final analysis. In 112 procedures an
EVD was inserted and in the remaining 119 procedures
a shunt was placed, including 112 ventriculoperitoneal
shunts, 2 ventriculoatrial shunts, 4 cyst-peritoneal
shunts and 1 subduro-peritoneal shunt. In 119 of them
AICs were employed, using non-AICs in the 112
remaining procedures. Both cohorts were homoge-
neous for the aforementioned independent variables
except for the type of CSF shunting device employed
(shunt versus EVD) and the follow-up (Table 2). In the
control cohort, EVDs percentage was significantly
higher (p = 0.005) and, therefore, median follow-up
was shorter (p = 0.002).
Infection was confirmed in 29 cases, 8 of them in the
treatment cohort and the remaining 21 in the control
cohort (Table 3). Staphylococcus epidermidis was the
main causative agent (51.7%), followed by GNB (37.9%)
and other agents (27.6%). Three EVDs (two of them
were AICs) were infected by multiple microorganisms,
being at least one of them a Staphylococcus spp. or a
GNB.
Overall infection rate was 12.6%. Univariate analysis
showed significant differences between the treatment
and the control cohorts (6.7% against 18.8%, respec-
tively; p = 0.006). Staphylococcal infection rate was 6.9%,
being the differences observed between both cohorts sig-
nificant as well (3.4% in the treatment cohort against
10.7% in the control cohort; p = 0.028). However, GNB
infection rate did not increase in the treatment cohort
(p = 0.303). After adjusting for follow-up by means of
Kaplan-Meier curve and univariate Cox regression analy-
sis, significant differences were shown as well (Figure 1).
An explicative multivariate analysis using Cox regression
model confirmed the decrease in overall and Staphylococ-
cal infection rates when using AICs (HR 0.41; CI 95%
0.18-0.96; p = 0.030 and HR 0.33; CI 95% 0.10-1.05; p =
0.045, respectively). Thus, AICs were associated with a
relative decrease of 59% in overall infection rate and a
relative decrease of 67% in Staphylococcal infection rate.
The number needed to treat (NNT) to prevent one infec-
t i o nw a s8 .T h eN N Tt op r e v e n to n eStaphylococcal
infection was 14.
Table 1 Independent variables
Shunts EVDs
EPIDEMIOLOGICAL VARIABLES EPIDEMIOLOGICAL VARIABLES
Age Age
≤6 months ≤6 months
7 months-14 years 7 months-14 years
15-69 years 15-69 years
≥70 years ≥70 years
Sex Sex
CLINICAL VARIABLES CLINICAL VARIABLES
CSF infection previous 6 months Diagnosis
Previous shunt -Traumatic brain injury
Diagnosis -Vascular disease
-Traumatic brain injury -Haemorrhagic CVA +/- intraventricular haemorrhage
-Vascular disease -Tumour
-Haemorrhagic CVA +/- intraventricular haemorrhage -Premature intraventricular haemorrhage
-Tumour -Others (malformative, infectious, post-surgical causes)
-Premature intraventricular haemorrhage Follow-up
-Normal-pressure hydrocephalus
-Others (malformative, infectious, post-surgical causes)
Follow-up
SURGICAL VARIABLES
Type of surgery
-De novo insertion
-Proximal revision
-Distal revision
-Full revision
EVD: external ventricular drain; CSF: cerebrospinal fluid; CVA: cerebrovascular accident.
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association between EVDs and infection risk was
observed, being the likelihood of overall infection 37.03
folds higher for EVDs than shunts (CI 95% 7.25-200.01;
p < 0.001), whereas the likelihood of Staphylococcal
infection was 16.13 folds higher (CI 95% 2.85-90.91; p <
0.001) for EVDs than shunts.
All patients presented excellent tolerance to AICs. No
local or systemic side-effects were described.
Stratified analysis
A stratified analysis was performed in order to minimize
the impact of the type of CSF shunting device (EVD
versus shunt) on infection.
Table 2 Baseline characteristics of all the procedures included for analysis: Cohorts’ comparison
No. PROCEDURESS (%) (n = 231)
VARIABLES TREATMENT COHORT (n = 119) CONTROL COHORT (n = 112) p value
Type of device EVD 47 (39.5) 65 (58.0) 0.005
Age: 0.600
≤6 months 12 (10.1) 10 (8.9) NS
7 months-14 years 10 (8.4) 15 (13.4) NS
15-69 years 71 (59.7) 67 (59.8) NS
≥70 years 26 (21.8) 20 (17.9) NS
Sex Male 68 (57.1) 64 (57.1) 1
Diagnosis: 0.182
Traumatic brain injury 8 (6.7) 10 (8.9) NS
Vascular disease 17 (14.3) 24 (21.4) NS
CVA +/- IVH 12 (10.1) 18 (16.1) NS
Tumour 33 (27.7) 18 (16.1) NS
Premature IVH 12 (10.1) 6 (5.4) NS
Normal-pressure hydrocephalus 17 (14.3) 16 (14.3) NS
Others 20 (16.8) 20 (17.9) NS
Follow-up, median (IQR), days 159 (11-518) 16 (9-266) 0.002
n: sample size; EVD: external ventricular drain; CVA: cerebrovascular accident; IVH: intraventricular haemorrhage; IQR: interquartilic range; NS: non significant.
Table 3 Aetiology of infections
Treatment cohort Control cohort Total
EVD Shunt Total EVD shunt total
Staphylococcus spp. 2247 51 2 16 (55.2%)
S. epidermidis 2247 41 1
S. aureus 0000 1 1
GNBs 4 0 4 5 2 7 11 (37.9%)
P. aeruginosa 0000 1 1
Acinetobacter spp. 2 0 2 1 0 1
Enterobacter spp. 1 0 1 1 0 1
E. coli 0001 0 1
Sphingomonas spp. 1 0 1 0 0 0
Klebsiella spp. 0 0 0 2 1 3
Other microorganisms 4 0 4 3 1 4 8 (27.6%)
Enterococcus spp. 2 0 2 2 0 2
Streptococcus spp. 0 0 0 0 1 1
Corynebacterium spp. 1 0 1 1 0 1
Candida spp. 1 0 1 0 0 0
Total (infection per procedure) 6/47 (12.8%) 2/72 (2.7%) 8/119 (6.7%) 13/65 (20%) 8/47 (17%) 21/112 (18.8%) 29/231 (12.6%)
EVD: external ventricular drain
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A total of 119 shunt procedures were included in this
study, employing AICs in 72 of them (60.5%). When
comparing basal characteristics of both cohorts, a signif-
icantly higher percentage of patients between 15 and 69
years old and of those who underwent de novo insertion
shunts was observed in the treatment cohort, while a
significantly higher percentage of patients between
7 months old and 14 years old and of those who under-
went full revision of the shunt was documented in the
control cohort (Table 4). Ten infections were confirmed
in this subgroup (2 in the treatment cohort and 8 in the
control cohort; overall infection rate 8.4%). Staphylococ-
cus spp. was the most frequent causative agent (70%),
followed by GNB (20%) and other microorganisms (10%.
See Table 3). Overall infection rate was significantly
lower when employing AICs (2.8% in the treatment
cohort against 17% in the control cohort; p = 0.014).
Staphylococcal infection rate was 5.9% (7/119). When
comparing control and treatment cohorts, the rate
decreased from 10.6% to 2.8% (p = 0.111). Only two
GNB infections were confirmed (1.7%), and both of
them appeared in the control cohort (p = 0.303). Uni-
variate Cox regression analysis showed a relative
decrease of 84% in overall infection rate (HR 0.16; CI
95% 0.03-0.73; p = 0.018) in AICs procedures (Figure 2).
In the multivariate analysis, the most important con-
founding factor (prior shunt) and the independent vari-
able to be studied (AICs) were included in final models.
Besides that, the independent variables associated with
increasing infection rate after univariate analysis (prior
CSF infection and full revision), were entered in a step-
wise fashion. As a result, the protective effect of AICs
against overall infection was significant in model 1 (HR
0.18; CI 95% 0.04-0.87; p = 0.016) and marginally signif-
icant in model 2 (HR 0.25; CI 95% 0.05-1.29; p = 0.071).
External ventricular drains
A total of 112 procedures with EVDs were included,
employing AICs in 47 of them (42%). Both cohorts were
homogeneous when comparing basal characteristics.
Median length of ventriculostomy was 9 days in the
treatment cohort and 10 days in the control cohort (p =
0.679). Nineteen infections were confirmed in this sub-
group (6 in the treatment cohort and 13 in the control
cohort; overall infection rate 17%). Staphylococcus spp.
and GNB were isolated in similar percentage of positive
cultures (47.4%), while other microorganisms were iso-
lated in 36.8% of positive cultures (Table 3). Overall
infection rate was lower in the treatment cohort (12.8%,
6/47) than in the control cohort (20%, 13/65; p = 0.310).
Staphylococcal infection rate was also lower in the study
cohort (4.3% against 10.8%), but these differences were
not statistically significant (p = 0.299). Gram-negative
bacilli infection rate was similar in both cohorts (p =1 ) .
Kaplan-Meier curve and univariate Cox regression
analysis adjusting for length of ventriculostomy did
not show significant differences between both cohorts
(Figure 3).
Discussion
Prevention strategies designed to control device-related
infectious complications have been determined in the
last decades by the knowledge and comprehension of
the mechanisms of infection involved. Given the impor-
tance that microorganism’s adherence to CSF shunting
catheters surface has achieved in the pathogenesis of
infection, the most promising strategies are focusing on
intrinsic treatment of the catheter surface in order to
enhance resistance to colonization phenomena [40].
There are a rising number of studies that support the
use of rifampicin and clindamycin impregnated catheters
in shunt procedures in order to reduce not only the
incidence but also the costs of device-related infectious
complications [11-18,25-27,29-32]. However, only two of
these studies mention the effect of AICs on Staphylococ-
cal infection [16,17]. Experience with EVDs is shorter,
since only two studies assessing rifampicin and clinda-
mycin impregnated catheters efficacy have been pub-
lished in the literature to date [17,34]. Besides that, two
more studies evaluating minocycline and rifampicin
impregnated EVDs have been reported [33,35].
The results obtained in the present retrospective study
show a significant reduction in infection at our centre in
those cases where AICs were used (p = 0.006) for CSF
shunting procedures. A multivariate analysis of data,
confirming that AICs are helpful and safe in reducing
infectious complications rate (p = 0.030), was achieved
Figure 1 Kaplan-Meier curve. Cumulative freedom from infection
according to antibiotic impregnation of the catheters. The risk of
device-related infection was significantly lower in those procedures
in which AICs were implanted compared with those procedures
with non-AICs (HR 0.29; 95% CI 0.13-0.65; p = 0.003).
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founding factors (the most relevant one may be the type
of CSF shunting device -internal versus external-).
Moreover, a significant decrease in Staphylococcal infec-
tion rate was observed in both univariate (p =0 . 0 2 8 )
and multivariate (p = 0.045) analyses. The use of these
catheters did not increase GNB infection rate. On the
contrary, a trend to reduce the infection caused by these
bacteria was observed, although the differences observed
Table 4 Baseline characteristics of shunt procedures: Cohorts’ comparison
No. PROCEDURES (%) (n = 119)
VARIABLES TREATMENT COHORT (n = 72) CONTROL COHORT (n = 47) p value
Age: 0.027
≤6 months 6 (8.3) 8 (17.0) NS
7 months-14 years 7 (9.7) 12 (25.5) 0.021
15-69 years 40 (55.6) 16 (34.0) 0.022
≥70 years 19 (26.4) 11 (23.4) NS
Sex Male 38 (52.7) 30 (63.8) 0.234
CSF infection in previous 6 months 16 (22.2) 10 (21.3) 0.903
Previous shunt 16 (22.2) 19 (40.4) 0.033
Diagnosis: 0.071
Traumatic brain injury 4 (5.6) 0 (0) NS
Vascular disease 6 (8.3) 3 (6.4) NS
CVA +/- IVH 1 (1.4) 0 (0) NS
Tumour 21 (29.2) 6 (12.8) NS
Premature IVH 6 (8.3) 5 (10.6) NS
Normal-pressure hydrocephalus 17 (23.6) 16 (34.0) NS
Others 17 (23.6) 17 (36.1) NS
Type of surgery: 0.001
De novo 55 (76.4) 27 (57.4) 0.029
Proximal revision 6 (8.3) 2 (4.3) NS
Distal revision 4 (5.5) 0 (0) NS
Full revision 7 (9.7) 18 (38.3) <0.001
Follow-up, median (IQR), days 384.5 (184-704.75) 385 (144-1085) 0.910
n: sample size; CSF: cerebrospinal fluid; CVA: cerebrovascular accident; IVH: intraventricular haemorrhage; IQR: interquartilic range; NS: non significant
Figure 2 Kaplan-Meier curve. Cumulative freedom from infection
in shunts according to antibiotic impregnation of the catheters. The
risk of shunt-related infection was significantly lower in those
procedures in which AICs were implanted compared with those
procedures with non-AICs (HR 0.16; 95% CI 0.03-0.73; p = 0.018).
Figure 3 Kaplan-Meier curve. Cumulative freedom from infection
in EVDs according to antibiotic impregnation of the catheters. The
risk of EVD-related infection was lower in those procedures in which
AICs were implanted compared with those procedures with non-
AICs. However, the differences observed were not statistically
significant (HR 0.70; 95% CI 0.26-1.87; p = 0.479).
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these results, rifampicin and clindamycin impregnated
catheters in both shunt and EVD procedures are shown
to be a helpful and safe tool to reduce and control the
incidence of infection after their use.
Despite the fact that it was not one of the prefixed
objectives of the study, multivariate analysis demon-
s t r a t e dt h a tE V D sw e r e3 7 . 0 3 - f o l dm o r el i k e l yt o
become infected than shunts, as well as 16.13-fold more
likely to become infected by Staphylococcus spp. than
shunts. Although it is widely accepted that EVDs risk of
infection is higher than shunts risk, to our knowledge
this is the first study that quantifies the increase in the
likelihood of infection associated to the former. External
ventricular drains removed before the fifth day following
insertion were excluded from this study with the pur-
pose of minimizing the false-negative rate, a bias that
must be considered. However, the results hereby
reported may approach the risk of infection assumed
when making the decision of implanting an EVD instead
of a shunt in certain patients.
A stratified analysis was performed depending on the
type of CSF shunting device employed with the aim of
minimizing as much as possible the impact of confound-
ing factors. Thus, in the subgroup of shunts, rifampicin
and clindamycin impregnated catheters were associated
with a significant decrease in overall infection (p =
0.014, univariate analysis). After multivariate analysis, a
marginally significant decrease in these complications
was also observed, with a relative reduction of 75% in
overall infection rate when employing AICs. These dif-
ferences have also been reported by other authors
[16,29]. Staphylococcal infection rate was importantly
reduced too -from 10.6% to 2.8%- when inserting AICs.
However this result was not statistically significant. This
fact could be explained by the low incidence of infec-
tious events, being necessary to increase the sample size
to obtain statistically relevant differences. Besides that,
the use of AICs did not increase GNB infection, a simi-
larity observed in other studies results [17,25].
Considering exclusively EVDs, AICs were associated
with a decrease from 20% to 12.8% in overall infection
rate and a decrease from 10.8% to 4.3% in Staphylococ-
cal infection rate (p = 0.310 and p = 0.299, respectively),
without increasing GNB infection rate. Once observed
the results obtained after multivariate analysis of the
whole sample, these findings could be explained by the
small sample size given the low incidence of infectious
events.
There are only two studies that have been published
in the literature to date which compare the incidence of
infection when employing rifampicin and clindamycin
impregnated EVDs against control catheters [17,34].
Despite the fact that both studies point to the usefulness
of these devices in reducing infectious complications,
they include a small number of procedures. Besides that,
the study carried out by Tamburrini et al. [34] includes
a specific subgroup of patients suffering from hydroce-
phalus secondary to posterior fossa tumours. Similarly,
the reports with minocycline and rifampicin impreg-
nated catheters show a significant reduction in infection
associated with the use of treated catheters [33,35].
However, a recent study reports a significant number of
false-negative results from minocycline and rifampicin
impregnated EVDs compared with non-antibiotic
impregnated EVDs [41]. This potential bias has not
been studied concerning rifampicin and clindamycin
impregnated catheters.
Another consideration is that the presence of infection
involves not only morbidity and mortality for the
patient, but increasing costs for the hospital as well.
One of the latest lines of research that remains incom-
plete is to determine if AICs reduce infection hospital
costs, despite their higher price when comparing to
non-AICs. Economical differences will be probably
important, given the increased cost derived from treat-
ing a CSF device-related infection when considering
intravenous antibiotic treatment, intensive care unit
stay, new CSF shunting device or prolonged hospital
stay. Although the difference in price between AICs and
non-AICs is easily measurable (differences around 100 €
in EVDs and 180 € in shunts), it is not so easy to quan-
tify the hospital cost derived from an infectious event.
This difficulty may be the main obstacle in designing a
study to assess these costs. Three studies have been
published in the literature in order to assess the impact
of antibiotic-impregnated shunts on hospital costs. All
of them suggest the economic effectiveness of the afore-
mentioned systems [13,14,30]. However, no study has
been performed with EVDs with this purpose, thus the
economical impact of AICs in this field remains
unknown.
Finally, the main limitations of this study derive from
i t sr e t r o s p e c t i v ed e s i g n ,a si td o e sn o tp r o v i d et h eb e s t
l e v e lo fs c i e n t i f i ce v i d e n c et od r a wc o n c l u s i o n s .M u l t i -
variate and stratified analyses were performed in order
to avoid the impact of possible confounding factors.
Besides that, data were exclusively collected by the first
author of this study with the aim of giving consistency
to data codification and in order to make database man-
agement easier.
Conclusions
The results obtained in this retrospective study suggest
that AICs are a protective and safe tool against infection
and, specifically, against Staphylococcus spp. infection.
The number needed to treat for AICs is 8 to prevent
one infection and 14 to prevent one staphylococcal
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Page 7 of 9infection. When comparing with shunts, the use of
EVDs is associated with a 37-fold increased likelihood of
infection. However, further prospective, randomized,
controlled trials are required to confirm these results.
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